Jefferies (NYSE:JEF) analyst Eun Yang maintained a Buy rating on Keros Therapeutics on Monday, setting a price target of $75, which is approximately 52.91% above the present share price of $49.05.
Yang expects Keros Therapeutics to post earnings per share (EPS) of -$0.87 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Keros Therapeutics, with an average price target of $93.33.
The analysts price targets range from a high of $105 to a low of $75.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$20.2 million. The company's market cap is $1.15 billion.
According to TipRanks.com, Jefferies analyst Eun Yang is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 6.5% and a 49.39% success rate.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.